{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T13:59:59Z","timestamp":1771336799332,"version":"3.50.1"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Checkpoint inhibitors targeting PD-1\/PD-L1, such as pembrolizumab, can be effective in a small population of biomarker-selected patients with metastatic prostate cancer (mPC), as has been demonstrated by small case series. The objective of this study is to help identify which biomarker-selected patients are most likely to benefit from pembrolizumab and estimate their likelihood of response. This is a single-center study in which we analyzed clinical data of 18 patients with mPC who were treated with pembrolizumab for a biomarker-driven indication. We found that 38.9% of patients showed a 50% or greater decline in PSA, all of whom had high microsatellite instability (MSI-H). One patient with MSI-H and high tumor mutation burden (TMB-H) had 100% decline in PSA and remained on pembrolizumab after 47 months. Neither MSI-H nor TMB-H, however, was sufficient for response. These results support biomarker testing for all patients with mPC and use of immunotherapy in select populations.<\/jats:p>","DOI":"10.1093\/oncolo\/oyaf025","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T16:57:51Z","timestamp":1741625871000},"source":"Crossref","is-referenced-by-count":4,"title":["Response to pembrolizumab in advanced prostate cancer with predictive biomarkers"],"prefix":"10.1093","volume":"30","author":[{"given":"Nicole J","family":"Altomare","sequence":"first","affiliation":[{"name":"Department of Medicine, Northwestern University , Chicago, IL 60611 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutai","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Northwestern University , Chicago, IL 60611 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clayton","family":"Neill","sequence":"additional","affiliation":[{"name":"Department of Urology, Northwestern University , Chicago, IL 60611 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha","family":"Hussain","sequence":"additional","affiliation":[{"name":"Department of Medicine, Northwestern University , Chicago, IL 60611 ,","place":["United States"]},{"name":"Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University , Chicago, IL 60611 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4576-5034","authenticated-orcid":false,"given":"David J","family":"VanderWeele","sequence":"additional","affiliation":[{"name":"Department of Medicine, Northwestern University , Chicago, IL 60611 ,","place":["United States"]},{"name":"Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University , Chicago, IL 60611 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"2025031016574440100_CIT0001","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"2025031016574440100_CIT0002","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"2025031016574440100_CIT0003","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","article-title":"Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade","volume":"5","author":"Abida","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025031016574440100_CIT0004","doi-asserted-by":"publisher","first-page":"e001065","DOI":"10.1136\/jitc-2020-001065","article-title":"Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA","volume":"8","author":"Barata","year":"2020","journal-title":"J ImmunoTher Cancer."},{"key":"2025031016574440100_CIT0005","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1001\/jamaoncol.2023.6817","article-title":"Tumor mutational burden in metastatic castration-resistant prostate cancer and response to checkpoint inhibition","volume":"10","author":"Zang","year":"2024","journal-title":"JAMA Oncol"},{"key":"2025031016574440100_CIT0006","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1200\/po.19.00383","article-title":"CDK12-mutated prostate cancer: clinical outcomes with standard therapies and immune checkpoint blockade","volume":"4","author":"Schweizer","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"2025031016574440100_CIT0007","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1200\/po.19.00399","article-title":"CDK12-altered prostate cancer: clinical features and therapeutic outcomes to standard systemic therapies, poly (ADP-Ribose) polymerase inhibitors, and PD-1 inhibitors","volume":"4","author":"Antonarakis","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"2025031016574440100_CIT0008","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1158\/1078-0432.CCR-24-0400","article-title":"Evaluating immune checkpoint blockade in metastatic castration-resistant prostate cancers with deleterious CDK12 alterations in the phase 2 IMPACT trial","volume":"30","author":"Nguyen","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2025031016574440100_CIT0009","doi-asserted-by":"publisher","first-page":"28561","DOI":"10.18632\/oncotarget.25564","article-title":"Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer","volume":"9","author":"Boudadi","year":"2018","journal-title":"Oncotarget"},{"key":"2025031016574440100_CIT0010","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s40425-018-0463-2","article-title":"Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations","volume":"6","author":"Karzai","year":"2018","journal-title":"J ImmunoTher Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/3\/oyaf025\/62368941\/oyaf025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/3\/oyaf025\/62368941\/oyaf025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T16:57:59Z","timestamp":1741625879000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf025\/8068846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,10]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf025","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,3]]},"article-number":"oyaf025"}}